<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560167</url>
  </required_header>
  <id_info>
    <org_study_id>5018</org_study_id>
    <nct_id>NCT03560167</nct_id>
  </id_info>
  <brief_title>Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation</brief_title>
  <acronym>CorCinch-PMVI</acronym>
  <official_title>An Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation - The CorCinch-PMVI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ancora Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ancora Heart, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, prospective, multi-center Early Feasibility Study of the AccuCinch®&#xD;
      Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and&#xD;
      Recurrent Mitral Regurgitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Device name changed from AccuCinch® Ventricular Repair System to AccuCinch® Ventricular&#xD;
      Restoration System, FDA Approval Date August 14, 2020.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Actual">March 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by device-related or procedure-related major adverse events (MAEs)</measure>
    <time_frame>30-day</time_frame>
    <description>Device-related or procedure-related major adverse events (MAEs)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathy, Dilated</condition>
  <arm_group>
    <arm_group_label>AccuCinch® Ventricular Restoration System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AccuCinch® Ventricular Restoration System</intervention_name>
    <description>AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation</description>
    <arm_group_label>AccuCinch® Ventricular Restoration System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study patient is at least 18-years old&#xD;
&#xD;
          -  Severity of FMR: ≥ Moderate (i.e., ≥2+, according to Stone et al Clinical Trial Design&#xD;
             Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and&#xD;
             Replacement: Part 1: Clinical Trial Design Principles. A Consensus Document from the&#xD;
             Mitral Valve Academic Research Consortium1; and 2003 ASE Guidelines for grading mitral&#xD;
             regurgitation2)&#xD;
&#xD;
          -  Patient has had a prior surgical or percutaneous mitral repair procedure &gt;3 months&#xD;
             prior to enrollment&#xD;
&#xD;
          -  LV Ejection Fraction: ≥20 to ≤40%&#xD;
&#xD;
          -  Symptom Status: NYHA II-IV (i.e., ambulatory)&#xD;
&#xD;
          -  Prescribed appropriate guideline-directed medical therapy for heart failure for at&#xD;
             least 3 months with stable doses of diuretics, beta-blockers and Angiotensin&#xD;
             converting enzyme inhibitor (ACEi) or Angiotensin II Receptor Blockers (ARB) for 1&#xD;
             month (with stable defined as no greater than 100% increase of 50% decrease in&#xD;
             medication doses). Treatment shall include CRT and/or ICD when indicated by&#xD;
             guidelines.&#xD;
&#xD;
          -  Able and willing to complete all qualifying diagnostic and functional tests and agrees&#xD;
             to comply with study follow-up schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with significant organic mitral valve pathology (e.g. myxomatous&#xD;
             degeneration, mitral valve prolapse or flail leaflets)&#xD;
&#xD;
          -  Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular&#xD;
             surgery, or carotid surgery within 3 months&#xD;
&#xD;
          -  Prior surgical, transcatheter, or percutaneous mitral valve replacement&#xD;
&#xD;
          -  Untreated clinically significant coronary artery disease (CAD) requiring&#xD;
             revascularization&#xD;
&#xD;
          -  Hemodynamic instability: Hypotension (systolic pressure &lt;90 mmHg) or requirement for&#xD;
             inotropic support or mechanical hemodynamic support&#xD;
&#xD;
          -  Any planned cardiac surgery or interventions within the next 6 months (including right&#xD;
             heart procedures)&#xD;
&#xD;
          -  NYHA class IV (i.e., non-ambulatory)&#xD;
&#xD;
          -  Fixed pulmonary artery systolic pressure &gt;70 mmHg&#xD;
&#xD;
          -  Severe tricuspid regurgitation&#xD;
&#xD;
          -  History of stroke within the prior 3 months or any prior stroke with Modified Rankin&#xD;
             Scale ≥ 4 disability&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or&#xD;
             any other structural heart disease causing heart failure other than dilated&#xD;
             cardiomyopathy of either ischemic or non-ischemic etiology&#xD;
&#xD;
          -  Anatomical pathology or constraints preventing appropriate access/implant of the&#xD;
             AccuCinch® Ventricular Repair System (e.g., femoral arteries will not support a 20F&#xD;
             system)&#xD;
&#xD;
          -  Renal insufficiency (i.e., eGFR of &lt;30ml/min/1.73m2; Stage 4 or 5 CKD)&#xD;
&#xD;
          -  Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis&#xD;
&#xD;
          -  Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile&#xD;
             aortic atheroma, intracardiac mass, thrombus or vegetation&#xD;
&#xD;
          -  Active bacterial endocarditis&#xD;
&#xD;
          -  Subjects in whom anticoagulation or antiplatelet therapy is contraindicated&#xD;
&#xD;
          -  Known allergy to nitinol, polyester, or polyethylene&#xD;
&#xD;
          -  Any prior true anaphylactic reaction to contrast agents; defined as known&#xD;
             anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that&#xD;
             cannot be adequately pre-medicated prior to the index procedure.&#xD;
&#xD;
          -  Life expectancy &lt; 1 year due to non-cardiac conditions&#xD;
&#xD;
          -  Currently participating in another interventional investigational study&#xD;
&#xD;
          -  Implant or revision of any rhythm management device (CRT or CRT-D) prior 3 months or&#xD;
             implantable cardioverter defibrillator within the prior 1 month&#xD;
&#xD;
          -  Subjects on high dose steroids or immunosuppressant therapy&#xD;
&#xD;
          -  Female subjects who are pregnant, of child bearing potential without a documented&#xD;
             birth control method, or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <role>Study Director</role>
    <affiliation>Ancora Heart, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kendra Grubb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guilherme Silva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor / St. Luke's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Foundation Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PinnacleHealth Cardiovascular Institute</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Health Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia School of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Tech Carilion School of Medicine and Research Institute</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

